Literature DB >> 9030401

Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats.

R Liljequist1, A Haapalinna, M Ahlander, Y H Li, P T Männistö.   

Abstract

Two catechol O-methyltransferase inhibitors, peripherally acting entacapone and also centrally acting tolcapone, were tested regarding their capacity to influence learning and memory in adult intact rats. Tolcapone was also studied in rats treated with scopolamine, in adult rats lesioned in the nuclei basalis magnocellularis, and in aged rats. Spatial working memory performance (radial-arm maze) of intact rats was facilitated following pretraining i.p. administration of tolcapone (10 mg/kg). Entacapone was ineffective at doses of 10 and 30 mg/kg. Senescent poor performers improved their accomplishment in the spatial memory task (linear-arm maze) under the influence of tolcapone. Scopolamine (1 mg/kg) impaired working memory performance. Bilateral lesions in the nucleus basalis magnocellularis reduced choline acetyltransferase activity in the frontal cortex by 26% and retarded the learning rate of spatial place task. Tolcapone was not able to counteract the performance deficits in these models. It is concluded that tolcapone can either slightly improve or impair the memory functions depending on task specific elements and performance factors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9030401     DOI: 10.1016/s0166-4328(97)80989-8

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  17 in total

Review 1.  Imaging genomics and response to treatment with antipsychotics in schizophrenia.

Authors:  Giuseppe Blasi; Alessandro Bertolino
Journal:  NeuroRx       Date:  2006-01

2.  Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice.

Authors:  Eric R Detrait; Greg V Carr; Daniel R Weinberger; Yves Lamberty
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

3.  Effect of tolcapone on brain activity during a variable attentional control task: a double-blind, placebo-controlled, counter-balanced trial in healthy volunteers.

Authors:  Sophia C Magalona; Roberta Rasetti; Jingshan Chen; Qiang Chen; Ian Gold; Heather Decot; Joseph H Callicott; Karen F Berman; José A Apud; Daniel R Weinberger; Venkata S Mattay
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

Review 4.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex.

Authors:  C C Lapish; S Ahn; L M Evangelista; K So; J K Seamans; A G Phillips
Journal:  Psychopharmacology (Berl)       Date:  2008-10-15       Impact factor: 4.530

Review 6.  Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments.

Authors:  Thomas W McAllister; Tim A Ahles; Andrew J Saykin; Robert J Ferguson; Brenna C McDonald; Lionel D Lewis; Laura A Flashman; C Harker Rhodes
Journal:  Curr Psychiatry Rep       Date:  2004-10       Impact factor: 5.285

Review 7.  Recent advances in treating cognitive impairment in schizophrenia.

Authors:  Cherrie Galletly
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

Review 8.  Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs.

Authors:  José A Apud; Daniel R Weinberger
Journal:  NeuroRx       Date:  2006-01

Review 9.  Catechol-O-methyltransferase polymorphisms and some implications for cognitive therapeutics.

Authors:  Catherine M Diaz-Asper; Daniel R Weinberger; Terry E Goldberg
Journal:  NeuroRx       Date:  2006-01

Review 10.  Genetic polymorphisms in the expression and treatment of neuropsychiatric disorders.

Authors:  Thomas W McAllister; Lanier Summerall
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.